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Improving the conduct, reporting, and appraisal of
animal research
All stakeholders must act decisively to fix endemic problems
Merel Ritskes-Hoitinga professor, Kim Wever researcher
SYRCLE, Department for Health Evidence, Radboudumc, Nijmegen, Netherlands
Preclinical animal studies aim to establish safety and efficacy
before patients are exposed to new treatments. However, the
translational success rate from animal studies to humans is quite
low, and the non-reproducibility of preclinical studies ranges
between 51% and 89%.1 The inadequate conduct, reporting, and
evaluation of animal research underpinning human trials is one
reason why big promises of better outcomes for patients so often
remain unfulfilled.
Improvements in the design, registration, reporting, and
transparency of animal studies are urgently needed. To achieve
this, we need a cultural change in which researchers are
rewarded for producing valid and reproducible results that are
relevant to patients, and for doing justice to the animals being
used. The MVA85A vaccine story (doi:10.1136/bmj.j5845),2 is
an example of a case where a more thorough analysis of
preceding animal studies could have resulted in better targeting
of resources in human studies.2 3
What are the essential next steps to make animal research more
fit for purpose as a valuable and reliable forerunner to clinical
research in humans? Systematic reviews of animal studies have
been instrumental in exposing the current limitations within
preclinical evidence and identifying reasons for translational
failure.4-6 For example, human clinical trials initiated after
positive results of individual animal studies have found zero
benefit or even harm—an outcome that could have been
prevented by a careful systematic review of all animal studies
before the launch of the clinical trial.3 7 This is the first step up,
akin to the improvements in reporting of clinical trials prompted
by the establishment of the Cochrane collaboration in 1992.
Integrating systematic reviews of animal studies into the
Cochrane framework would boost cross fertilisation with clinical
systematic reviews.
Systematic reviews of animal studies have also exposed the
high risk of reporting biases in this research, especially
publication bias and selective reporting of outcomes. Prospective
registration of animal study protocols is crucial to prevent these
biases. Registration of clinical trials is commonly mandatory,
but it remains rare for animal studies. This will hopefully change
with the recent launch of www.preclinicaltrials.eu, a registration
platform for animal studies.
Journals should make prospective registration a condition of
publication and should provide their editors and reviewers with
tools to help identify selective outcome reporting and HARKing
(hypothesising after results are known) in submitted manuscripts.
Funders of animal research should also demand registration,
along with high quality open access publication of results or
registration of full methods and outcome data. If final methods
and results are not made public in a timely manner, future
funding should be withheld.
Systematic reviews of animal studies should become
commonplace. Importantly, they must be high quality. This
means prospective registration of all review protocols, enabled
by a recent extension to PROSPERO, the registry of systematic
reviews in health; use of unbiased methods, as assessed by
validated methods such as the ROBIS (risk of bias in systematic
reviews) tool; and full reporting using the forthcoming extension
to PRISMA (preferred reporting items for systematic reviews
and meta-analyses).
When preclinical evidence is critical to a decision to start a
clinical trial, ethics committees should demand that all preceding
animal studies are systematically reviewed, including (if
possible) an assessment of the certainty of the evidence
according to GRADE principles.8 Regulatory bodies such as
the US Food and Drug Administration and the European
Medicines Agency should also become more demanding
regarding the robustness of the preclinical evidence that
underpins licensing applications. Since synthesis of preclinical
evidence is a highly specialised field, an external expert should
lead the quality assessment of evidence summaries and advise
regulators on their interpretation.
The poor reporting of methods and findings must be addressed
in both primary animal studies and subsequent systematic
reviews. The ARRIVE (animals in research: reporting in vivo
experiments) guidelines for reporting in vivo experiments,9
embedded in the instructions for authors by at least 600 journals
since 2010, had in 2014 not resulted in the hoped for
improvements in study reporting.10 11 And as long as it is possible
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to publish in high impact factor journals without having to
satisfy the ARRIVE guidelines, current practice is unlikely to
change. Journals should take responsibility for full and
transparent reporting of animal studies, including flexible or
even absent word limits for online reporting of methods. Editors
should make sure that articles do not enter the review process
without completion of ARRIVE or other official reporting
guidelines. A recent roundtable with editors, funders, and
academia concluded that academic institutions also need to act
now if scientists are to be skilled in reliable and reproducible
studies.12
By definition, to research means to re-search. A systematic
review of preclinical animal studies is genuine re-search and a
solid basis for subsequent clinical trials. If the responsible bodies
mentioned above succeed in making a culture change,
demanding high quality reporting and systematic reviews of
animal studies, the potential of animal studies to transform
human health will be realised.
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